- $304.51m
- $478.50m
- $114.20m
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income
Agenus Inc expected to post earnings of 5 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology
U.S. STOCKS ON THE MOVE-American Express, Deckers, Q32 Bio
U.S. STOCKS ON THE MOVE-American Express, Deckers, Q32 Bio
Agenus secures up to $340 mln to advance colon cancer drug into late-stage study; shares jump
Brief: Agenus Announces Three-Year Survival Data From Phase 1B Bot+Bal Study In Mss Metastatic Colorectal Cancer To Be Presented At Esmo Gi 2026
Brief: Agenus Reports First Quarter 2026 Financial Results And Highlights Bot+Bal Execution Across Global Access And Phase 3 Development
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit
Brief: Agenus Reports Phase Ii Data Demonstrating Immune Reprogramming And Durable Survival With Botensilimab, Balstilimab And Agent-797 In Pd-1 Refractory Gastroesophageal Cancer
NASDAQ RESUMED AT 10:48 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:43 AM
NASDAQ RESUMED AT 10:43 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:33 AM
Brief: Agenus Appoints Dr. José Iglesias As Chief Medical Affairs Officer To Guide Global Medical Affairs And Early-Access Programs, Including France’S Aac